Nature Medicine, Published online: 24 July 2026; doi:10.1038/s41591-026-04496-2
In the LITMUS study, serum biomarkers outperformed imaging for identifying patients at risk of MASH, whereas elastography was superior for staging advanced fibrosis and cirrhosis.
